ClinicalTrials.gg
RecruitingNCT06593314Updated Nov 5, 2026

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

An interventional study of Message with EchoGo and Standard Message in Heart Failure and Diabetes, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Failure by University of Texas Southwestern Medical Center — 7 open to participants now, 7 under way, 2 of them phase 3. Heart Failure · University of Texas Southwestern Medical Center.

Planned enrollment
3rd of 19
800 · median 104
Started
2025
with 3 others
No phase
11 of 22
4 open now
Registered
18th of 22
by date

Among the 22 studies in Heart Failure by University of Texas Southwestern Medical Center, this one is the 3rd largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, and was the 18th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 22 studies in Heart Failure by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Failure by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

Read the detailed description

Historic echocardiograms will be analyzed using the Ultromics EchoGo algorithm. For patients that have a positive EchoGO result i.e. HFpEF detected, the provider will get an clinical decision support alert flagging high risk of HFpEF based on randomized assignment.

Experimental: Alert Group Provider will receive a computer-based provider-to-provider message notifying the provider that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors, non-steroidal MRA, or GLP-1 RA (if obesity is present). The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided. The investigators will assess the practice patterns of providers in response to the EHR-based alert over the study period (3, and 6-month follow-up). The investigators will also assess the downstream hospitalization events for HF within 12 months of the initial alert.

Control arm: Standard Message Providers in the control group will receive a standard message that will recommend either SGLT2i, GLP-1RA, and/or ns-MRA for treatment of diabetes and for prevention of heart failure. This group will not receive any information about the presence of subclinical heart failure detected by the EchoGo algorithm. The investigators will monitor the practice pattern in this group as well over the study period.

Follow Up. Adherence to SGLT-2i and GLP-1 RA medications will be assessed by evaluating the electronic health record and documenting if the patient had a follow-up with a healthcare provider at 3 and 6 months and medication listed in the active prescription medication list.

Sample Size: The investigators plan to enroll 800 anticipated patients using a parallel design with 1:1 allocation and a binary primary endpoint (SGLT2i use). Using a two-sample test for difference in proportions with the normal (Fleiss) approximation, pooled variance without continuity correction, and assuming a control proportion of 30%, α=0.05 (two-sided), and 80% power, an N=800 (400/arm) provides a minimum detectable absolute increase of \~9.4 percentage points (30.0% to 39.4% in the intervention arm). This corresponds to RR = 1.31(95% CI 1.08, 1.59) and Cohen's h = 0.20.

03

Conditions studied

  • Heart Failure
  • Diabetes

Keywords

  • Subclinical Heart Failure; Electronic Alerts; Diabetes
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Clinical cohort inclusion exclusion criteria:

Inclusion criteria

Inclusion Criteria:

  • Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
  • Echocardiogram available in last 6-months.

Exclusion criteria

Exclusion Criteria:

  • History of HF
  • Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA

Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    EHR Alert Group

    Provider will receive a computer-based alert notifying them that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors and/or GLP-1 RA (if obesity is present). The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided

    Behavioral: Message with EchoGo

  • Active comparator
    Standard Message Group

    We will provide a standard message to the provider detailing guideline-recommended medications for type 2 diabetes. This will not contain information about the Ultromics EchoGo algorithm. The providers can choose to provide care as deemed fit based on the information provided

    Behavioral: Standard Message

Interventions

  • BehavioralMessage with EchoGo

    This alert will inform the provider that the patient has subclinical HFpEF

    Also known as: EchoGo Message

  • BehavioralStandard Message

    This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.

06

What researchers measure

Primary outcomes

  1. Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up

    Frequency of prescription of SGLT-2i medication at outpatient clinic visits will be measured as the proportion of new prescription for SGLT2inhibitor divided by the number of alerts triggered.

    Time frame: 3-month follow-up

  2. Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up

    Frequency of prescription of SGLT-2i medication at outpatient clinic visits will be measured as the proportion of new prescription for GLP1 divided by the number of alerts triggered.

    Time frame: 3-month follow-up

Secondary outcomes

  1. Frequency of prescription of ns-MRA at outpatient clinic visits

    Frequency of prescription of ns-MRA at outpatient clinic visits will be measured as the proportion of new prescription for ns-MRA divided by the number of alerts triggered.

    Time frame: 6-months

  2. Frequency of prescription of GLP-1 RA medication at outpatient clinic visits over

    Frequency of prescription of GLP-1 RA medication at outpatient clinic visits over will be measured as the proportion of new prescription for GLP1 divided by the number of alerts triggered.

    Time frame: 6 months follow-up

  3. Heart Failure hospitalization

    Counts of heart failure hospitalization will be recorded form the electronic health record

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
    Recruiting
    • Ambarish Pandey, MD,MSCS · Contact214-645-9762
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 21 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → May 2027 and completion Oct 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Aug 6, 2025
Primary completionEst.
May 15, 2027was Sep 2026
CompletionEst.
Jul 15, 2027was Oct 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 15, 2026→May 15, 2027
Nov 5, 2026
Study completion
Oct 15, 2026→Jul 15, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Sep 15, 2026→May 15, 2027
    Study completion Oct 15, 2026→Jul 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06593314
Responsible party
Ambarish Pandey (Associate Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 19, 2024
Start date
Aug 6, 2025
Primary completion
May 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Ambarish Pandey, MD
Contact
Ambarish.Pandey@UTSouthwestern.edu
617-869-8957
Ambarish Pandey, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion